{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:29:28Z","timestamp":1791257368548,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-10339-7","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T05:52:47Z","timestamp":1734673967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predictors of treatment delay among drug resistant tuberculosis patients in Uganda"],"prefix":"10.1186","volume":"24","author":[{"given":"Nabukenya Diana","family":"Kasozi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lwanga","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asiimwe","family":"JohnBosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luzze","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"issue":"12","key":"10339_CR1","doi-asserted-by":"publisher","first-page":"e0244451","DOI":"10.1371\/journal.pone.0244451","volume":"15","author":"S Kasozi","year":"2020","unstructured":"Kasozi S, et al. Addressing the drug-resistant tuberculosis challenge through implementing a mixed model of care in Uganda. PLoS ONE. 2020;15(12):e0244451\u2013e0244451.","journal-title":"PLoS ONE"},{"issue":"2","key":"10339_CR2","first-page":"e35154","volume":"15","author":"K Chowdhury","year":"2023","unstructured":"Chowdhury K, et al. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) among children: Where we stand now. Cureus. 2023;15(2):e35154.","journal-title":"Cureus"},{"key":"10339_CR3","unstructured":"World Health Organisation [WHO], WHO Guidelines Approved by the Guidelines Review Committee, in Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. 2014: Geneva."},{"key":"10339_CR4","unstructured":"World Health Organisation [WHO], Global tuberculosis report 2023. 2023: Geneva."},{"key":"10339_CR5","unstructured":"World Health Organisation [WHO], WHO new global lists of high-burden countries for TB, HIV-associated TB and drug-resistant TB. 2021."},{"key":"10339_CR6","unstructured":"World Health Organisation [WHO], Tuberculosis profile: Uganda. 2021."},{"issue":"1","key":"10339_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13756-022-01101-2","volume":"11","author":"JM Kabahita","year":"2022","unstructured":"Kabahita JM, et al. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda. Antimicrob Resist Infect Control. 2022;11(1):68.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"1","key":"10339_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13756-019-0561-z","volume":"8","author":"IS Pradipta","year":"2019","unstructured":"Pradipta IS, et al. Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005\u20132015. Antimicrob Resist Infect Control. 2019;8(1):1\u201312.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"9","key":"10339_CR9","doi-asserted-by":"publisher","first-page":"a017863","DOI":"10.1101\/cshperspect.a017863","volume":"5","author":"KJ Seung","year":"2015","unstructured":"Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015;5(9):a017863\u2013a017863.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"10339_CR10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12879-021-05967-2","volume":"21","author":"E Kizito","year":"2021","unstructured":"Kizito E, et al. Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study. BMC Infect Dis. 2021;21(1):292.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"10339_CR11","doi-asserted-by":"publisher","first-page":"e0209932","DOI":"10.1371\/journal.pone.0209932","volume":"13","author":"YM Htun","year":"2018","unstructured":"Htun YM, et al. Delay in treatment initiation and treatment outcomes among adult patients with multidrug-resistant tuberculosis at Yangon Regional Tuberculosis Centre, Myanmar: A retrospective study. PLoS ONE. 2018;13(12):e0209932.","journal-title":"PLoS ONE"},{"issue":"1","key":"10339_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s12879-019-4112-2","volume":"19","author":"KT Tefera","year":"2019","unstructured":"Tefera KT, et al. Treatment delay and associated factors among adults with drug resistant tuberculosis at treatment initiating centers in the Amhara regional state, Ethiopia. BMC Infect Dis. 2019;19(1):489.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10339_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s12879-024-09328-7","volume":"24","author":"R Liao","year":"2024","unstructured":"Liao R, et al. Association between TB delay and TB treatment outcomes in HIV-TB co-infected patients: a study based on the multilevel propensity score method. BMC Infect Dis. 2024;24(1):457.","journal-title":"BMC Infect Dis"},{"key":"10339_CR14","doi-asserted-by":"crossref","unstructured":"Ye MinnHtun, Y.M.H., et al., Delay in treatment initiation and treatment outcomes among adult patients with multidrug-resistant tuberculosis at Yangon Regional Tuberculosis Centre, Myanmar: a retrospective study. PLoS ONE. 2018;13(12):e0209932.","DOI":"10.1371\/journal.pone.0209932"},{"issue":"4","key":"10339_CR15","doi-asserted-by":"publisher","first-page":"e02259","DOI":"10.1128\/AAC.02259-17","volume":"62","author":"Y Chen","year":"2018","unstructured":"Chen Y, et al. Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai China. Antimicrob Agents Chemother. 2018;62(4):e02259-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"10339_CR16","doi-asserted-by":"publisher","first-page":"100221","DOI":"10.1016\/j.jctube.2021.100221","volume":"23","author":"JB Baluku","year":"2021","unstructured":"Baluku JB, et al. Treatment outcomes of drug resistant tuberculosis patients with multiple poor prognostic indicators in Uganda: A countrywide 5-year retrospective study. J Clin Tuberc Other Mycobact Dis. 2021;23:100221.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"1","key":"10339_CR17","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1186\/s12879-021-06743-y","volume":"21","author":"MK Martin","year":"2021","unstructured":"Martin MK, et al. High rates of culture conversion and low loss to follow-up in MDR-TB patients managed at Regional Referral Hospitals in Uganda. BMC Infect Dis. 2021;21(1):1060.","journal-title":"BMC Infect Dis"},{"issue":"9","key":"10339_CR18","doi-asserted-by":"publisher","first-page":"e74023","DOI":"10.1371\/journal.pone.0074023","volume":"8","author":"L Nakiyingi","year":"2013","unstructured":"Nakiyingi L, et al. Clinical predictors and accuracy of empiric tuberculosis treatment among sputum smear-negative HIV-infected adult TB suspects in Uganda. PLoS ONE. 2013;8(9):e74023.","journal-title":"PLoS ONE"},{"key":"10339_CR19","unstructured":"MoH\/NTLP, U., Uganda National Guidelines for the Programmatic Management of Drug-resistant Tuberculosis, 2016 Second Edition, pg 1\u2013232. 2016."},{"key":"10339_CR20","unstructured":"MoH\/NTLP, U., Uganda National Guidelines For The Programmatic Management Of Drug Resistant Tuberculosis. 2011."},{"key":"10339_CR21","unstructured":"World Health Organisation [WHO], Consolidated guidance on tuberculosis data generation and use. Module 1. Tuberculosis surveillance. 2024: Geneva."},{"key":"10339_CR22","unstructured":"Fiona, S. and W. Elizabeth, Discrete-time Event History Analysis. 2013: p. 47."},{"key":"10339_CR23","unstructured":"Zach, B. How to Test for Multicollinearity in Stata. 2020 [cited 2023 31\/01\/2023]; Available from: https:\/\/www.statology.org\/multicollinearity-stata\/."},{"key":"10339_CR24","unstructured":"Abonazel, M. and M. Ghallab, On Estimation Methods for Binary Logistic Regression Model with Missing Values. 2018: p. 79\u201385."},{"issue":"4","key":"10339_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.4103\/ijph.IJPH_26_19","volume":"63","author":"A Bhagyalaxmi","year":"2019","unstructured":"Bhagyalaxmi A, et al. Reasons for the delay in the initiation of treatment and initial default among drug-resistant tuberculosis patients in Ahmedabad corporation area. Indian J Public Health. 2019;63(4):377\u20139.","journal-title":"Indian J Public Health"},{"key":"10339_CR26","doi-asserted-by":"crossref","unstructured":"van de Water, B.J., et al., Time to Drug-Resistant Tuberculosis Treatment in a Prospective South African Cohort. Glob Pediatr Health, 2017. 4: p. 2333794x17744140.","DOI":"10.1177\/2333794X17744140"},{"issue":"5","key":"10339_CR27","doi-asserted-by":"publisher","first-page":"e0251691","DOI":"10.1371\/journal.pone.0251691","volume":"16","author":"J Kabugo","year":"2021","unstructured":"Kabugo J, et al. Implementation of GeneXpert MTB\/Rif proficiency testing program: A Case of the Uganda national tuberculosis reference laboratory\/supranational reference laboratory. PLoS ONE. 2021;16(5):e0251691.","journal-title":"PLoS ONE"},{"key":"10339_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/IDR.S345619","volume":"15","author":"KS Tamirat","year":"2022","unstructured":"Tamirat KS, et al. The Role of GeneXpert MTB\/RIF in Reducing Treatment Delay Among Multidrug Resistance Tuberculosis Patients: A Propensity Score Matched Analysis. Infect Drug Resist. 2022;15:285\u201394.","journal-title":"Infect Drug Resist"},{"issue":"3","key":"10339_CR29","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3201\/eid2203.151227","volume":"22","author":"HR Stagg","year":"2016","unstructured":"Stagg HR, et al. Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB\/RIF Test. Latvia Emerg Infect Dis. 2016;22(3):482\u201390.","journal-title":"Latvia Emerg Infect Dis"},{"key":"10339_CR30","unstructured":"MoH\/NTLP, U., Addendum to the National Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, page I -59. June 2019."},{"issue":"7","key":"10339_CR31","doi-asserted-by":"publisher","first-page":"e39040","DOI":"10.1371\/journal.pone.0039040","volume":"7","author":"D Paul","year":"2012","unstructured":"Paul D, et al. Factors associated with delays in treatment initiation after tuberculosis diagnosis in two districts of India. PLoS ONE. 2012;7(7):e39040.","journal-title":"PLoS ONE"},{"issue":"1","key":"10339_CR32","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1186\/s12913-018-3583-y","volume":"18","author":"T Li","year":"2018","unstructured":"Li T, et al. Patient and health system delays before registration among migrant patients with tuberculosis who were transferred out in China. BMC Health Serv Res. 2018;18(1):786.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"10339_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/jammr\/2019\/v31i230282","volume":"31","author":"FF Chikuse","year":"2019","unstructured":"Chikuse FF, et al. Socio-demographic Factors Associated with Treatment Initiation Delays among Tuberculosis Patients in Namibia. J Adv Med Med Res. 2019;31(2):1\u201311.","journal-title":"J Adv Med Med Res"},{"issue":"1","key":"10339_CR34","doi-asserted-by":"publisher","first-page":"7695","DOI":"10.1038\/s41598-024-58080-0","volume":"14","author":"LW Limenh","year":"2024","unstructured":"Limenh LW, et al. Tuberculosis treatment outcomes and associated factors among tuberculosis patients treated at healthcare facilities of Motta Town, Northwest Ethiopia: a five-year retrospective study. Sci Rep. 2024;14(1):7695.","journal-title":"Sci Rep"},{"issue":"1","key":"10339_CR35","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12890-021-01735-9","volume":"21","author":"S Soedarsono","year":"2021","unstructured":"Soedarsono S, et al. Determinant factors for loss to follow-up in drug-resistant tuberculosis patients: the importance of psycho-social and economic aspects. BMC Pulm Med. 2021;21(1):360.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10339_CR36","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1186\/s12889-021-12005-y","volume":"21","author":"IS Pradipta","year":"2021","unstructured":"Pradipta IS, et al. Barriers and strategies to successful tuberculosis treatment in a high-burden tuberculosis setting: a qualitative study from the patient\u2019s perspective. BMC Pub Health. 2021;21(1):1903.","journal-title":"BMC Pub Health"},{"issue":"1","key":"10339_CR37","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41598-021-04345-x","volume":"12","author":"RM Ghazy","year":"2022","unstructured":"Ghazy RM, et al. A systematic review and meta-analysis of the catastrophic costs incurred by tuberculosis patients. Sci Rep. 2022;12(1):558.","journal-title":"Sci Rep"},{"issue":"1","key":"10339_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/00005650-197901000-00002","volume":"17","author":"MA Safer","year":"1979","unstructured":"Safer MA, et al. Determinants of three stages of delay in seeking care at a medical clinic. Med Care. 1979;17(1):11\u201329.","journal-title":"Med Care"},{"issue":"12","key":"10339_CR39","doi-asserted-by":"publisher","first-page":"e0208390","DOI":"10.1371\/journal.pone.0208390","volume":"13","author":"NS Kirirabwa","year":"2018","unstructured":"Kirirabwa NS, et al. Response to anti-tuberculosis treatment by people over age 60 in Kampala, Uganda. PLoS ONE. 2018;13(12):e0208390.","journal-title":"PLoS ONE"},{"issue":"12","key":"10339_CR40","doi-asserted-by":"publisher","first-page":"e0294254","DOI":"10.1371\/journal.pone.0294254","volume":"18","author":"P Giridharan","year":"2023","unstructured":"Giridharan P, et al. Recurrence of pulmonary tuberculosis in India: Findings from the 2019\u20132021 nationwide community-based TB prevalence survey. PLoS ONE. 2023;18(12):e0294254.","journal-title":"PLoS ONE"},{"issue":"1","key":"10339_CR41","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1186\/s12879-022-07622-w","volume":"22","author":"H Jiang","year":"2022","unstructured":"Jiang H, et al. Epidemiology of recurrent pulmonary tuberculosis by bacteriological features of 100 million residents in China. BMC Infect Dis. 2022;22(1):638.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10339_CR42","doi-asserted-by":"publisher","first-page":"ofab340","DOI":"10.1093\/ofid\/ofab340","volume":"8","author":"SH Gan","year":"2021","unstructured":"Gan SH, et al. Recurrent Tuberculosis Disease in Singapore. Open Forum Infect Dis. 2021;8(7):ofab340.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10339_CR43","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12879-021-05994-z","volume":"21","author":"SJ Li","year":"2021","unstructured":"Li SJ, et al. Population aging and trends of pulmonary tuberculosis incidence in the elderly. BMC Infect Dis. 2021;21(1):302.","journal-title":"BMC Infect Dis"},{"issue":"8","key":"10339_CR44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/antibiotics9080489","volume":"9","author":"F Di Gennaro","year":"2020","unstructured":"Di Gennaro F, et al. Active Pulmonary Tuberculosis in Elderly Patients: A 2016\u20132019 Retrospective Analysis from an Italian Referral Hospital. Antibiotics (Basel). 2020;9(8):489.","journal-title":"Antibiotics (Basel)"},{"key":"10339_CR45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ijid.2014.11.018","volume":"32","author":"J Negin","year":"2015","unstructured":"Negin J, Abimbola S, Marais BJ. Tuberculosis among older adults\u2013time to take notice. Int J Infect Dis. 2015;32:135\u20137.","journal-title":"Int J Infect Dis"},{"key":"10339_CR46","unstructured":"USAID\/UGANDA, MONITORING EVALUATION AND LEARNING PROGRAM. TRACK TB- A mixed methods assessment strategies, partnerships, leverage points and learnings. 2016:1\u2013131. . 2016."},{"key":"10339_CR47","unstructured":"MoH\/NTLP Uganda, Uganda expansion plan 2012\u20132016 and operational guidance on programmatic management of drug resistant TB. 2012. . 2012."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10339-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10339-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10339-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T06:03:25Z","timestamp":1734674605000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10339-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["10339"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10339-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4083618\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study employed routine NTLP DR-TB program data without patient participation, but gained administrative authorization to access the data from NTLP. As the study did not utilize any personal identifiable information, obtaining patient consent was unnecessary. Moreover, there were no anticipated risks or advantages to the patients resulting from the examination of this data. Nevertheless, the researchers obtained ethical approval from both the Makerere School of Social Sciences Research and Ethics Committee (REC) with a reference number (MAKSSREC 11.22.610\/PRI) and the Uganda National Council for Science and Technology(UNCST) with a reference number HS2653ES.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1452"}}